Clinical Research
Our Team of Experts More than 20 specialists work together to provide the best possible care for each patient 
|
|
|
In chemotherapy, Memorial Sloan-Kettering research helped establish the efficacy of irinotecan, the first new drug for colorectal cancer in 40 years. In some patients, this drug shrinks metastatic tumors when other treatment fails.
Our researchers led an international trial demonstrating that irinotecan in combination with fluorouracil and leucovorin was a more effective first-line therapy for advanced colorectal cancer, and they are now leading a large study to evaluate the combination's effectiveness in earlier-stage colorectal cancer. Oxaliplatin is another new drug in the treatment of colorectal cancer available in a clinical research program.
New Technologies for Advanced Cancers
Patients whose disease has spread to the liver benefit from a comprehensive program that includes doctors from colorectal surgery, hepatobiliary surgery, and medical oncology who work together to maximize long-term survival.
Intrahepatic Pump
Chemotherapy delivered directly to the liver can shrink tumors more effectively than that given through a vein in the arm. Memorial Sloan-Kettering has an active program developing new technologies to deliver chemotherapy through a pump placed directly into the hepatic artery, which leads to the liver. To learn more, please visit our clinical trial database.